Evotec (ETR:EVT) has been given a €25.00 ($29.07) price target by investment analysts at Deutsche Bank in a research report issued to clients and investors on Thursday, September 5th, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Deutsche Bank’s price target would suggest a potential upside of 20.71% from the stock’s current price.
Separately, Berenberg Bank set a €28.00 ($32.56) price target on shares of Evotec and gave the stock a “neutral” rating in a report on Thursday, August 1st.
ETR:EVT opened at €20.71 ($24.08) on Thursday. The company has a current ratio of 3.24, a quick ratio of 3.01 and a debt-to-equity ratio of 99.79. The stock has a market capitalization of $3.12 billion and a PE ratio of 40.77. The firm’s 50 day moving average is €22.66 and its 200 day moving average is €22.81. Evotec has a 12 month low of €15.00 ($17.44) and a 12 month high of €27.29 ($31.73).
Evotec Company Profile
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Read More: Understanding Options Trading
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.